Therapeutic effect of spleen aminopeptide oral lyophilized powder on children with mycoplasma pneumoniae pneumonia and its influence on serum Gal-3 and sB7-H3 expression
Objective To investigate the therapeutic effect of spleen aminopeptide oral lyophilized powder on children with mycoplasma pneumoniae pneumonia(MPP)and its influence on the expression of serum galectin-3(Gal-3)and soluble B7-H3(sB7-H3).Methods A total of 80 children with MPP admitted to Xinglin Branch of the First Affiliated Hospital of Xiamen University from August 2022 to February 2023 were randomly divided into the control group(n=40)and the study group(n=40)according to the random number table method.The control group received conventional treatment,and the study group received conventional treatment plus oral lyze-dried splenic peptide treatment.The clinical efficacy,symptom improvement,serum Gal-3 and sB7-H3 expression levels and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of children in the study group(95.00％)was significantly higher than that in the control group(72.50％),with a statistically significant difference(P＜0.05).The time to clinical symptom disappearance,the average length of stay and the duration for white blood cell count to return to normal in the study group were significantly shorter than those in the control group,with statistically significant differences(P＜0.05).After treatment,the serum levels of Gal-3 and sB7-H3 in the study group were significantly lower than those in the control group,with statistically significant differences(P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(12.50％vs.15.00％)(P＞0.05).Conclusion Spleen aminopeptide oral lyophilized powder can significantly increase the clinical efficacy,improve the clinical signs and reduce the expression levels of serum Gal-3 and sB7-H3 in MPP children,with high safety.
万方数据
